James M. Mock Sells 689 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) CFO James M. Mock sold 689 shares of the company’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the sale, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at $859,486.56. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Moderna Stock Up 1.2 %

Shares of MRNA stock opened at $117.44 on Thursday. The firm’s fifty day moving average price is $135.42 and its two-hundred day moving average price is $113.61. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $170.47. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $45.01 billion, a P/E ratio of -7.49 and a beta of 1.66.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The business had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same quarter in the previous year, the business earned $0.19 earnings per share. Moderna’s quarterly revenue was down 91.0% on a year-over-year basis. On average, equities analysts predict that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Moderna

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ogorek Anthony Joseph NY ADV bought a new position in shares of Moderna in the fourth quarter valued at $27,000. Arlington Trust Co LLC lifted its stake in Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after acquiring an additional 290 shares during the last quarter. Cedar Wealth Management LLC grew its position in shares of Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares during the period. Westside Investment Management Inc. acquired a new position in shares of Moderna during the 1st quarter worth about $32,000. Finally, Rise Advisors LLC raised its holdings in shares of Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after purchasing an additional 286 shares during the period. Institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on MRNA shares. Oppenheimer upped their target price on shares of Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a research note on Wednesday, June 12th. Canaccord Genuity Group raised their price objective on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research note on Friday, May 3rd. Evercore ISI reissued an “in-line” rating and issued a $120.00 target price on shares of Moderna in a research note on Thursday, June 27th. UBS Group raised their price target on Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Finally, William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $134.02.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.